Partnering opportunity

An established Slovak research institute has developed a unique system for in vivo isolation of circulating tumour cells from peripheral blood and is looking for licensees or investors

Summary

An established Slovak scientific and research institute in cooperation with a traditional Slovak university have developed a unique system for in vivo isolation of circulating tumour cells from peripheral blood. The system allows repeated CTCs (circulating tumour cells) isolation from the whole blood volume without blood leaving the bloodstream or sampling it. They are looking for licensee or investor partners from the industry, dealing with cancer diagnostics and personalised medicine.

Partner sought

Type: company (industry) Field of activity: especially molecular diagnostics of cancer and personalized medicine. Role: License agreement - the Slovak research institute is looking for licensees Financial agreement - an investor into this technology is sought.

Description

Each tumour releases cells into the patient's blood or lymphatic system which subsequently enter various parts of the body, creating secondary tumour deposits - metastases. These cells are called circulating tumour cells (CTCs). Their detection in blood has prognostic significance and also allows observing changes in tumour properties in real time. Due to a very low amount of CTCs in the blood, the biological and clinical knowledge of CTCs are strongly dependent on isolation parameters and the technology used to increase the detection success. Existing methods for CTCs detection do not allow a detailed characterization of CTCs, as the amount of isolated CTCs is usually very small. A team of inventors from the Slovak research institute in cooperation with Slovak university has developed a unique system for in vivo isolation of circulating tumour cells from peripheral blood. The institute was established in 1953 in order to carry out fundamental and applied research and new developments in the field of civil engineering and architecture. The university which was engaged in the development process belongs to well-known university with the strong expertise in biotech. This innovative technology takes advantage of magnetic nanoparticles coated with a monoclonal antibody that are injected into the bloodstream via an intravenous cannula, as well as of a special wire containing a magnetic core coated with a non-magnetic mantle. The principle of isolation of circulating cells from peripheral blood according to this unique solution is as follows: Magnetic nanoparticles coated with a monoclonal antibody are injected into the vein through a venous cannula, while their position is controlled using magnets. The nanoparticles are exposed to circulating tumour cells. After in vivo incubation the nanoparticles are moved closer to the venous cannula by the movement of large magnets and a special wire comprising a magnetic core coated with a non-magnetic mantle is inserted through the cannula into the blood stream. Large magnets are removed and nanoparticles are attracted by the magnetic wire. Magnetic wire coated with nanoparticles with attached CTCs is removed from the cannula and placed in a test tube with a suitable medium. The magnetic core is removed and the nanoparticles with attached CTCs are released into the medium for further analysis. The research institute is looking for partners to cooperate with via license agreement (the Slovak research institute is looking for licensees) or via financial agreement (an investor is sought).

Advantages and innovations

Competitive advantages: - In vivo isolation of CTCs and/or CSCs (cancer stem cell) - Isolation of CTCs and/or CSCs from the whole volume of patient’s blood - Detection of CTCs and/or CSCs in very low concentrations - More effective than available solutions - Universal solution that may be adapted to any type of blood cells - Easy and straightforward manipulation Its biggest advantage over existing solutions lies especially in the fact, that this system makes it possible to isolate more CTCs (or other cells present in peripheral blood) than other methods.

Development stage

Concept stage

Intellectual Property Rights (IPR)

Patents granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

What next?

To finish up, we just need some extra details about you and your company